Dr. van der Loo has been a director in GMP viral vector manufacturing since 2002. He was a founder and served as the Director of the Vector Production Facility at the Cincinnati Children’s Hospital Medical Center from 2002 to 2015. Since 2015, he has been the Director of the Clinical Vector Core at the Children’s Hospital of Philadelphia (CHOP). His expertise includes process development and manufacturing of pre-clinical and clinical grade vectors on several viral vector platforms, including gamma-retrovirus, lentivirus and AAV. In addition, he was involved in the design, commissioning and qualification of several GMP cleanroom facilities. The Clinical Vector Core at CHOP has manufactured viral vectors in support of 27 clinical trials, at phases 1, 2 and 3, in 10 countries. Dr. van der Loo is a member of the Editorial Board of Molecular Therapy – Methods & Clinical Development and Translational Science and Product Development Committee of the American Society of Gene & Cell Therapy (ASGCT). He is a member of the 4Bio Ventures Management Advisory Board and serves as consultant in several capacities.